Penumbra shareholders approve merger with Boston Scientific
Penumbra shareholders have voted to approve the merger with Boston Scientific, clearing a key procedural hurdle for the deal to close. With shareholder approval in hand, the remaining risk centers on regulatory clearance and the final deal mechanics for BSX.
What happened
Penumbra shareholders have voted to approve the merger with Boston Scientific, clearing a key procedural hurdle for the deal to close.
The read · Jul 5
With PEN shareholders approving the BSX merger, the question is whether the remaining deal spread offers meaningful risk-adjusted return or whether regulatory risk keeps it wider than it should be.
Wrong if
FTC or DOJ opens a formal investigation into neurovascular device market concentration, delaying or blocking the deal and causing PEN to gap down significantly from deal price.
CoverageSource: Investing.com · Published here SUN, JUL 5 · 5:30 AM ET · the only report in this recordHow this is decided →
The chart · PENTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Penumbra (PEN) shareholders have formally approved the proposed acquisition by Boston Scientific (BSX), removing one of the last major contingent risks in the deal process. Penumbra reported $1.4B in revenue for FY2025, up 17.5% year-over-year, with a solid 67.1% gross margin — a high-quality neurovascular and vascular asset that justified BSX's interest. Boston Scientific itself posted $20.1B in revenue, growing nearly 20% YoY, underscoring its capacity to absorb and integrate a mid-cap MedTech like Penumbra.
The shareholder vote is a pivotal de-risking event for deal-spread traders. PEN shares will now trade much closer to the deal price, leaving minimal upside unless the spread has not fully closed. BSX bears the integration risk and the capital outlay, but gains a fast-growing neurovascular platform that complements its existing portfolio.
For deal-spread players, the key remaining catalyst is regulatory approval — any DOJ or FTC scrutiny of the neurovascular device market could delay or complicate closing. BSX's strong revenue growth and margins suggest it can manage the acquisition without diluting its own financial profile materially, but any deal premium it paid will weigh on near-term EPS accretion math.
The practical trade here is narrow: PEN arbitrage spread against the announced deal price, with residual risk only from regulatory disruption. BSX's own stock is more of a longer-duration story around integration success and whether Penumbra's 17.5% revenue growth trajectory is preserved post-close.
The read, in fullWhy it matters
Shareholder approval removes the largest contingent risk for the merger; the remaining spread, if any, is essentially a regulatory risk premium. PEN's strong 17.5% revenue growth and 67.1% gross margins make it an unlikely antitrust target given its niche neurovascular positioning. BSX's own 20% revenue growth and scale suggest manageable integration.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from JUL 6 on
Next · what would move this
Until deal close, likely 1-3 months. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD+4.2%
JUL 6 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
▲ The case it holds
With shareholder approval now secured and PEN operating in a relatively niche neurovascular segment, regulatory clearance is the most likely outcome, implying the spread should close fully and deliver the remaining arb return.
▼ The case it breaks
Heightened antitrust scrutiny under the current regulatory environment could delay or complicate closing, keeping the spread wider longer or — in a tail scenario — forcing a renegotiation of deal terms.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →